PK and Safety Study of BIIB074 in Healthy Japanese and Caucasian Participants
A Phase 1 Pharmacokinetics and Safety Study of BIIB074 in Healthy Japanese and Caucasian Subjects
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
-
Leeds, Regno Unito, LS2 9LH
- Research Site
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Key Inclusion Criteria:
- Japanese or Caucasian.
- Japanese participants must have been born in Japan, and their biological parents and grandparents must all have been of Japanese origin.
- Must have a body mass index between 18 and 30 kg/m2, inclusive.
Key Exclusion Criteria:
- Previous exposure to BIIB074, with the exception that Japanese participants who complete Part 1.
- Use of any oral, injected, or implanted hormonal method of contraception that contains ethinyl estradiol within 28 days of Day -1 and an unwillingness to refrain from product use during study participation.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Triplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Part 1
48 participants: Cohorts 1,2 and 3 (Single Ascending Dose of BIIB074 or placebo) in a 6:2 ratio
|
Somministrato come specificato nel braccio di trattamento
Altri nomi:
Placebo abbinato
|
|
Sperimentale: Part 2
16 participants: Multiple Ascending Dosing of BIIB074 or placebo in a 6:2 ratio; 3 times daily [TID] in cohort 4 for 6 days and one time (QD) for 1 day and 2 times daily [BID] in cohort 5 for 6 days and QD for 1 day
|
Somministrato come specificato nel braccio di trattamento
Altri nomi:
Placebo abbinato
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Part 1: PK of BIIB074 single oral dose as assessed by maximum observed concentration (Cmax )
Lasso di tempo: 15 minutes prior to dosing up to 96 hours post dose
|
15 minutes prior to dosing up to 96 hours post dose
|
|
Part 1: PK of BIIB074 single oral dose as assessed by time to reach Cmax (tmax)
Lasso di tempo: 15 minutes prior to dosing up to 96 hours post dose
|
15 minutes prior to dosing up to 96 hours post dose
|
|
Part 1: PK of BIIB074 single oral dose as assessed by area under the concentration time curve from time 0 extrapolated to infinity (AUCinf)
Lasso di tempo: 15 minutes prior to dosing up to 96 hours post dose
|
15 minutes prior to dosing up to 96 hours post dose
|
|
Part 1: PK of BIIB074 single oral dose as assessed by area under the concentration time curve from time 0 to time of the last measurable drug concentration (AUC0-t)
Lasso di tempo: 15 minutes prior to dosing up to 96 hours post dose
|
15 minutes prior to dosing up to 96 hours post dose
|
|
Part 1: PK of BIIB074 single oral dose as assessed by terminal elimination half-life (t1/2)
Lasso di tempo: 15 minutes prior to dosing up to 96 hours post dose
|
15 minutes prior to dosing up to 96 hours post dose
|
|
Part 1: PK of BIIB074 single oral dose as assessed by apparent volume of distribution (Vd/F)
Lasso di tempo: 15 minutes prior to dosing up to 96 hours post dose
|
15 minutes prior to dosing up to 96 hours post dose
|
|
Part 1: PK of BIIB074 single oral dose as assessed by apparent total body clearance (CL/F)
Lasso di tempo: 15 minutes prior to dosing up to 96 hours post dose
|
15 minutes prior to dosing up to 96 hours post dose
|
|
Part 1: PK of BIIB074 single oral dose as assessed by metabolite to parent ratio in AUC (MRAUC)
Lasso di tempo: 15 minutes prior to dosing up to 96 hours post dose
|
15 minutes prior to dosing up to 96 hours post dose
|
|
Part 2: PK of BIIB074 repeated oral dose as assessed by Cmax
Lasso di tempo: 15 minutes prior to dosing on Day 1 up to 96 hours post dose on Day 7
|
15 minutes prior to dosing on Day 1 up to 96 hours post dose on Day 7
|
|
Part 2: PK of BIIB074 repeated oral dose as assessed by tmax
Lasso di tempo: 15 minutes prior to dosing on Day 1 up to 96 hours post dose on Day 7
|
15 minutes prior to dosing on Day 1 up to 96 hours post dose on Day 7
|
|
Part 2: PK of BIIB074 repeated oral dose as assessed by area under the concentration time curve within a dosing interval (AUCtau)
Lasso di tempo: 15 minutes prior to dosing on Day 1 up to 96 hours post dose on Day 7
|
15 minutes prior to dosing on Day 1 up to 96 hours post dose on Day 7
|
|
Part 2: PK of BIIB074 repeated oral dose as assessed by trough concentration after repeated doses (Ctrough)
Lasso di tempo: 15 minutes prior to dosing on Day 1 up to 96 hours post dose on Day 7
|
15 minutes prior to dosing on Day 1 up to 96 hours post dose on Day 7
|
|
Part 2: PK of BIIB074 repeated oral dose as assessed by t1/2
Lasso di tempo: 15 minutes prior to dosing on Day 1 up to 96 hours post dose on Day 7
|
15 minutes prior to dosing on Day 1 up to 96 hours post dose on Day 7
|
|
Part 2: PK of BIIB074 repeated oral dose as assessed by apparent volume of distribution at steady state (Vss/F)
Lasso di tempo: 15 minutes prior to dosing on Day 1 up to 96 hours post dose on Day 7
|
15 minutes prior to dosing on Day 1 up to 96 hours post dose on Day 7
|
|
Part 2: PK of BIIB074 repeated oral dose as assessed by apparent clearance at steady state (CLss/F)
Lasso di tempo: 15 minutes prior to dosing on Day 1 up to 96 hours post dose on Day 7
|
15 minutes prior to dosing on Day 1 up to 96 hours post dose on Day 7
|
|
Part 2: PK of BIIB074 repeated oral dose as assessed by accumulation ratio (Rac)
Lasso di tempo: 15 minutes prior to dosing on Day 1 up to 96 hours post dose on Day 7
|
15 minutes prior to dosing on Day 1 up to 96 hours post dose on Day 7
|
|
Part 2: PK of BIIB074 repeated oral dose as assessed by MRAUC
Lasso di tempo: 15 minutes prior to dosing on Day 1 up to 96 hours post dose on Day 7
|
15 minutes prior to dosing on Day 1 up to 96 hours post dose on Day 7
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Number of participants experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)
Lasso di tempo: Up to 2 weeks post Part 2 of the Treatment Period
|
Up to 2 weeks post Part 2 of the Treatment Period
|
|
Number of participants with clinically significant laboratory assessment abnormalities
Lasso di tempo: Up to 2 weeks post Part 2 of the Treatment Period
|
Up to 2 weeks post Part 2 of the Treatment Period
|
|
Number of participants with clinically significant vital sign abnormalities
Lasso di tempo: Up to 2 weeks post Part 2 of the Treatment Period
|
Up to 2 weeks post Part 2 of the Treatment Period
|
|
Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities
Lasso di tempo: Up to 2 weeks post Part 2 of the Treatment Period
|
Up to 2 weeks post Part 2 of the Treatment Period
|
|
Number of participants with clinically significant physical examinations abnormalities
Lasso di tempo: Up to 2 weeks post Part 2 of the Treatment Period
|
Up to 2 weeks post Part 2 of the Treatment Period
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie del sistema nervoso
- Dolore
- Manifestazioni neurologiche
- Malattie neuromuscolari
- Malattie stomatognatiche
- Malattie della bocca
- Malattie del sistema nervoso periferico
- Malattie dei nervi cranici
- Malattie del nervo facciale
- Malattie del nervo trigemino
- Nevralgia facciale
- Nevralgia
- Nevralgia del trigemino
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 802HV106
- 2016-000874-39 (Numero EudraCT)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .